Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $6.52 and last traded at $6.53, with a volume of 2079355 shares trading hands. The stock had previously closed at $6.86.
Analyst Ratings Changes
Separately, Sanford C. Bernstein raised Coloplast A/S to a “hold” rating in a research note on Wednesday, January 28th. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, Coloplast A/S has an average rating of “Hold”.
Read Our Latest Research Report on CLPBY
Coloplast A/S Stock Down 4.8%
Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last issued its earnings results on Friday, February 6th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.01. Coloplast A/S had a return on equity of 27.87% and a net margin of 14.35%.The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.12 billion. On average, equities analysts expect that Coloplast A/S Sponsored ADR will post 0.31 EPS for the current year.
About Coloplast A/S
Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.
In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.
Featured Articles
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.
